Perspective Therapeutics (CATX) Stock Price, News & Analysis

Company Overview

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

Key Stats

• Today's Range: $6.02 to $6.87
• 50-Day Range: $6.78 to $15.84
• 52-Week Range: $2.28 to $19.05
• Volume: 1.16 million shs
• Average Volume: 704,527 shs
• Market Capitalization: $416.35 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $21.57
• Consensus Rating: Buy

Perspective Therapeutics Stock Analysis - MarketRank™

Perspective Therapeutics scored higher than 55% of companies evaluated by MarketBeat, and ranked 534th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Perspective Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Perspective Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Perspective Therapeutics are expected to decrease in the coming year, from ($0.86) to ($1.17) per share.

Price to Book Value per Share Ratio

Perspective Therapeutics has a P/B Ratio of 2.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for CATX.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Perspective Therapeutics does not currently pay a dividend.

Dividend Growth

Perspective Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for CATX.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.86

News Sentiment

Perspective Therapeutics has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for Perspective Therapeutics this week, compared to 3 articles on an average week.

Search Interest

Only 4 people have searched for CATX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Perspective Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Perspective Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.52% of the stock of Perspective Therapeutics is held by insiders.

Percentage Held by Institutions

54.66% of the stock of Perspective Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CATX Stock Analysis - Frequently Asked Questions

How have CATX shares performed this year?

Perspective Therapeutics' stock was trading at $11.90 at the start of the year. Since then, CATX shares have decreased by 48.2% and is now trading at $6.16.
View the best growth stocks for 2024 here.

How were Perspective Therapeutics' earnings last quarter?

Perspective Therapeutics, Inc. (NYSE:CATX) announced its earnings results on Tuesday, November, 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.21). The company earned $0.37 million during the quarter. Perspective Therapeutics had a negative net margin of 4,096.66% and a negative trailing twelve-month return on equity of 27.40%.

When did Perspective Therapeutics' stock split?

Perspective Therapeutics's stock reverse split on Monday, June 17th 2024. The 1-10 reverse split was announced on Monday, June 17th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are Perspective Therapeutics' major shareholders?

Perspective Therapeutics' top institutional investors include FMR LLC (8.16%), Janus Henderson Group PLC (7.10%), State Street Corp (3.24%) and Nicholson Wealth Management Group LLC (2.57%). Insiders that own company stock include Lantheus Alpha Therapy, Llc, Lori A Woods, Markus Puhlmann, Robert F Williamson III, Jonathan Robert Hunt and Johan M Spoor.
View institutional ownership trends.

How do I buy shares of Perspective Therapeutics?

Shares of CATX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Perspective Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Perspective Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Visa (V) and Chevron (CVX).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 11/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NYSE:CATX
• Previous Symbol: NYSE:CATX
• CUSIP: N/A
• CIK: 728387
• Web: www.perspectivetherapeutics.com
• Phone: 206-676-0900
• Fax: 509-267-3670
• Employees: 116
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $21.57
• High Stock Price Target: $27.00
• Low Stock Price Target: $17.00
• Potential Upside/Downside: +250.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 9 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-46,510,000.00
• Net Margins: -4,096.66%
• Pretax Margin: -3,780.02%
• Return on Equity: -27.40%
• Return on Assets: -23.16%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.60
• Quick Ratio: 9.60

Sales & Book Value

• Annual Sales: $1.43 million
• Price / Sales: 291.16
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.67 per share
• Price / Book: 2.31

Miscellaneous

• Outstanding Shares: 67,590,000
• Free Float: 65,209,000
• Market Cap: $416.35 million
• Optionable: Optionable
• Beta: 1.46